J. Goldman & Co’s Fate Therapeutics FATE Stock Holding History

J. Goldman & Co’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-209,000	Closed	-$1.28M	–	371
2017 Q4	$1.28M	Buy	+209,000	New	+$933K	0.07%	220

Other funds holding FATE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

J. Goldman & Co's FATE Position: Q1 2018 in Review

J. Goldman & Co sold out of Fate Therapeutics (FATE) in Q1 2018, closing a stake of 209,000 shares — an estimated $1.28M sold.

J. Goldman & Co first reported a position in FATE in Q4 2017 and held it in 1 quarter. The position peaked at $1.28M in Q4 2017. 90 funds tracked by Wall St. Rank hold FATE as of Q1 2018.

J. Goldman & Co reported no remaining Fate Therapeutics position as of Q1 2018 after selling out during the quarter.
J. Goldman & Co sold 209,000 Fate Therapeutics shares in Q1 2018, an estimated $1.28M.
J. Goldman & Co first reported a position in Fate Therapeutics in Q4 2017 and held it in 1 quarter.
J. Goldman & Co's Fate Therapeutics position peaked at $1.28M in Q4 2017.
90 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2018.

Based on J. Goldman & Co's 13F filing for Q1 2018, filed 15 May 2018.